Emerging drugs for chronic myeloid leukemia

Expert Opinion on Emerging Drugs

Volumn 15, Issue 2, 2010, Pages 175-184

  Cilloni, Daniela ^a   Messa, Emanuela ^a   Rotolo, Antonia ^a   Saglio, Giuseppe ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

BCR ABL; Chronic myeloid leukemia; Ph chromosome; Targeted therapy

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; 4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; ALPHA INTERFERON; ANTILEUKEMIC AGENT; ARSENIC TRIOXIDE; BAYER; BOSUTINIB; CORDYCEPIN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTARABINE; DANUSERTIB; DASATINIB; ENTINOSTAT; HOMOHARRINGTONINE; IDRONOXIN; IMATINIB; INCB 18424; NILOTINIB; NPB 001 056; PANOBINOSTAT; PERIFOSINE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; STA 9090; TEMSIROLIMUS; TIPIFARNIB; TOPOTECAN; UNCLASSIFIED DRUG; XL 228;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; LUNG EDEMA; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NAUSEA; NONHUMAN; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PLEURA EFFUSION; RASH; REVIEW; SINGLE DRUG DOSE; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; DRUGS, INVESTIGATIONAL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PRACTICE GUIDELINES AS TOPIC; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME;

EID: 77952798847     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728211003621220     Document Type: Review

References (71)

1. Chronic myelogenous leukemia V.I.2008. NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network, 2008. Available from: www.nccn.org/professionals/ physician-gls/PDF/cml.pdf. [Last accessed 19 September 2008]
2. Baccarani M, Cortes J, Pane F, et al. Chronic Myeloid Leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-6051
3. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007;7:441-453
4. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by 210 bcr-abl gene of the Philadelphia chromosome. Science 1990;87:6649-6653
5. Elefanty AG, Hariharan IK, Cory S. Bcr-Abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J 1990;9:1069-1078
6. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA 1990;87:6649-6653
7. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like disease in mice receiving p210bcr-abl- transformed bone marrow. Blood 1998;92:3780-3792
8. Heisterkamp N, Jenster G, ten Hoeve J. Acute leukaemia in bcr/abl transgenic mice. Nature 1990;344:251-253
9. Heisterkamp N, Jenster G, ten Hoeve J. Acute leukaemia in bcr/abl transgenic mice. Nature 1990;344:251-253
10. Ben-Neriah Y, Daley G Q, Mes-Masson A, et al. The chronic myelogenous leukemiaspecific p210 protein is the product of the bcr-abl hybrid gene Science 1986;233:212-214
11. Cortes J. Natural history and staging of chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004;18:569-584 (Pubitemid 38969132)
12. Melo J.V. The diversity of Bcr-Abl fusion proteins and their relationship to leukemia phenotype. Blood 1996;88:2375-2384
13. Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006;91:513-521
14. Guilhot F, Chastang C, Michallet M, et al. Interferon alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997;337:223-229
15. Giralt SA, Arora M, Goldman JM, et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 2007;137:461-467
16. Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002;8:935-942
17. Druker BJ, Talpaz M, Resta D, et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037
18. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukaemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042
19. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New Engl J Med 2002;346:645-652
20. Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukaemia after failure of interferon-alpha treatment. Blood 2008;111:1039-1043
21. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukaemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-3539 (Pubitemid 34534519)
22. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-1937 (Pubitemid 34525471)
23. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004
24. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417
25. Volpe G, Panuzzo C, Ulisciani S, Cilloni D. Imatinib resistance in CML Cancer Lett 2009;274:1-9
26. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in themanagement of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-1820
27. Hochhaus A, Kantarjian H, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109:2303-2309 (Pubitemid 46425867)
28. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540-3546
29. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6- methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-6661
30. Mauro MJ, Baccarani M, Cervantes F, et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). J Clin Oncol 2008;26:abstract 7009
31. Porkka K, Martinelli G, Ottmann O, et al. Dasatinib efficacy in patients with imatinib-resistant/-intolerant Philadelphia-chromosome-positive acute lymphoblastic leukemia: 24-month data from START-L. Haematologica 2008;93s1:1 abstract 001
32. Rea D, Dombret H, Kim DW, et al. Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia in accelerated phase 24-month data from START-A. Haematologica 2008;93s1:391 abstract 0982
33. Saglio G, Dombret H, Rea D, et al. Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia in blast phase: 24-month data from the START program. Haematologica 2008;93s1:349 abstact 0880
34. Hochhaus A, Branford S, Radich J, et al. Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR-ABL mutations. J Clin Oncol 2007;25: abstact 7023
35. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401
36. Burgess MR, Skaggs BJ, Shah NP, et al. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 2005;102:3395-3400
37. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101:690-698
38. Li S. Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma 2008;49:19-26
39. Ingley E. Src family kinases: regulation of their activities, levels and identification of new pathways. Biochim Biophys Acta 2008;1784:56-65
40. Stanglmaier M, Warmuth M, Kleinlein I, et al. The interaction of the BCR-ABL tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains. Leukemia 2003;17:283-289
41. Klejman A, Schreiner SJ, Nieborowska-Skorska M, et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukaemia cells. EMBO J 2002;21:5766-5774
42. Warmuth M, Bergmann M, Priess A, et al. The Src family kinase Hck interacts with BCR-ABL by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J Biol Chem 1997;272:33260-33270
43. Kappes DJ. CD4 and CD8: hogging all the Lck. Immunity 2007;5:691-693
44. Hu Y, Liu Y, Pelletier S, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1?induced B?lymphoblastic leukaemia but not chronic myeloid leukemia. Nature Genet 2004;36:453-461
45. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006;107:4532-4539
46. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL. Cancer Cell 2005;7:29-141
47. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-2551 (Pubitemid 43882350)
48. Kantarjian H, Hochhaus A, Cortes J, et al. Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CML-CP) patients with imatinib-resistance or intolerance. ASH Annual Meeting Abstract Book. Blood 2007;110:abstract 735
49. le Coutre P, Ottmann OG, Giles F. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 111:1834-1839
50. Ottmann O, Larson R, Kantarjian H, et al. Nilotinib monotherapy in patients with imatinib-resistant or -intolerant Ph+ chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL). Haematologica 2007;92: abstract 556
51. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-4505
52. Mueller MC, Erben P, Ernst T, et al. Molecular response according to type of preexisting BCR-ABL mutations after second line dasatinib therapyin chronic phase CML patients. ASH Annual Meeting Abstract Book. Blood 2007;110: abstract 319
53. Golas JM, Arndt K, Etienne C, et al. SKI-606, a 4-anilino-3- quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003;63:375-381
54. Kimura S, Naito H, Segawa H, et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005;106:3948-3954
55. Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib resistant BCR-ABL+ neoplastic cells. Cancer Res 2006;66:11314-11322
56. Cortes J, Kantarjian HM, Baccarani M, et al. A phase 1/2 study of SKI-606, a dual Inhibitor of Src and Abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatinib. ASH Annual Meeting Abstract Book. Blood 2006;108: abstract 168
57. Naito H, Kimura S, Nakaya Y, et al. In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations. Leuk Res 2006;30:1443-1446
58. Yokota A, Kimura S, Masuda S, et al. INNO?406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 2007;109:306-314
59. Giles FJ, Cortes JE, Jones D, et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007;109:500-502
60. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nature Rev Mol Cell Biol 2003;4:842-854
61. Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005;102:11011-11016
62. Shah NP, Skaggs B, Branford S, et al. The most common dasatinib-resistant BCR- ABL kinase domain mutations in patients with chronic myeloid leukemia are sensitive to VX-680: rationale for early combination kinase inhibitor therapy. ASH Annual Meeting Abstract Book. Blood 2006;108:abstract 2175
63. Adrián FJ, Ding Q, Sim T, et al. Allosteric inhibitors of BCR-ABL dependent cell proliferation. Nature Chem Biol 2006;2:95-102
64. Gumireddy K, Baker SJ, Cosenza SC, et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci USA 2005;102:1992-1997
65. Quintás-Cardama A, Cortes J. Omacetaxine mepesuccinate-a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies. Drugs 2008;5:356-372
66. Rubio-Viqueira B, Hidalgo M. Targeting mTOR for cancer treatment. Curr Opin Investig Drugs 2006;7:501-512
67. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100-104
68. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-566
69. Dierks C, Beigi R, Guo GR, et al. Expansion of BCR-ABL positive leukemic stem cells is dependent on hedgehog pathway activation. Cancer Cell 2008;14:238-249
70. Young MA, Shah NP, Chao, et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the aurora kinase inhibitor VX-680. Cancer Res 2006;66:1007-1014
71. Giles FJ, Cortes JE, Jones D, et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007;109:500-502